

Stockholm, 17 January 2012

Alan Raffensperger appointed Chief Operating Officer

Alan Raffensperger has been appointed Chief Operating Officer (COO) of Sobi with responsibility for Sales & Marketing, Supply Chain, Procurement and IT. His most recent position was CEO of Benechill Inc., an American medical device company within the hypothermia therapeutic field. During the years 2005 to 2010 he was employed by the American company Amgen and served as Executive Director, Head of Nephrology 2008-2010 based at the international headquarters in Switzerland, and General Manager of the Nordic and Baltic region 2005-2008, based in Sweden. Prior to that he was Sales and Marketing Director at Roche Pharmaceuticals, Sweden 1999-2004, Vice President, Global Marketing Diabetes Care at Roche Diagnostics 1996-1998 based in Germany, and Business Director Europe, Diabetes Care at Boehringer Mannheim 1994-1996, also based in Germany. He has also held leading positions within Pharmacia in Sweden and USA.

Alan Raffensperger, born in 1960, holds a Bachelor of Science from University of Maryland, Baltimore, USA. He will report to CEO Geoffrey McDonough and be a member of the Executive Leadership Team. The appointment takes effect immediately.

“We are delighted to welcome Alan to Sobi. The role of COO is part of the changes we are making to increase the effectiveness of our commercial operation. Alan brings an appropriate mix of operational and leadership experience in a variety of roles which will help to foster the evolution of Sobi in the years ahead,” says Geoffrey McDonough, CEO of Sobi.

For further information, please contact:

Åsa Stenqvist, Head of Communications and Investor Relations
Tel.: +46 8 697 21 88

Swedish Orphan Biovitrum (Sobi)

Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the health of rare disease patients and their families. The product portfolio comprises about 60 marketed products as well as projects in the late clinical phase. Key therapeutic areas are Inflammation and Genetics & Metabolism. In 2010 Sobi had revenues of SEK 1.9 billion and around 500 employees. The share (STO: SOBI) is listed on OMX NASDAQ Stockholm. More information is available at www.sobi.com.

The information above has been published pursuant to the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on 17 January 2012 at 11:15 a.m. CET.

Please follow the link below for a picture of Alan Raffensperger.

<http://www.sobi.com/Investors--Media/Imagebank/Senior-Management/>